What happens to clinical skills when AI does the routine work?
-
By
-
Doug Brunk
-
September 1, 2026
-
7 min
By
Doug Brunk
September 1, 2026
In the single-arm REFOCUS trial, 46% of patients responded to treatment, with a median response duration of 11.8 months.
September 24, 2026
Phase 3 VERIFY results showed a 77% clinical response rate during weeks 20 to 32.
August 31, 2026
The phase 2/3 ENERGY trial evaluated durable hemoglobin response with nipocalimab vs placebo in adults with warm autoimmune hemolytic anemia.
August 25, 2026